Shawn Tedman is the Director of the Clinical Trials Business at 23andMe, the first and only direct-to-consumer genetic testing company with FDA-authorized health reports.
Shawn has deep clinical operations and technology expertise gained in both biopharmaceutical and contract research environments. He has built and scaled global feasibility, site intelligence, and clinical technology teams with a focus on patient centricity and trial optimization.
In this role Shawn is leveraging this expertise in order to empower 23andMe’s customers to take control of their health and gain access to innovative therapeutic options through clinical trials. Shawn holds an MBA from Duke University.